http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008181874-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c41cabf02f0abdd1c3673a0219ea64f4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2007-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9bba39a360af035ccab8c5b5ed5818a |
| publicationDate | 2008-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2008181874-A1 |
| titleOfInvention | Cell composition and method for treating cancer |
| abstract | The invention provides, in part, novel cell compositions derived from tumor cell lines. Included are an AKCV-1 cell line deposited under ATCC ______, an AKCV-1-GM cell deposited under ATCC ______, and an AKCV-1 cell that is transfected with interferon alpha. Also provided is a cell composition comprising a tumor cell line that is transfected with GMCSF, and a tumor cell line that is transfected with interferon alpha. The invention further relates to therapeutic and non-therapeutic uses of the novel cell lines. Therapeutic applications of the presently disclosed cell lines include the use of the cell lines as whole cell cancer vaccines. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10046049-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010042189-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9492482-B2 |
| priorityDate | 2007-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 865.